Study on Generic Fingolimod
For some time now, the patent protection for the multiple sclerosis (MS) drug Gilenya® (Fingolimod) has expired – the active ingredient Fingolimod can therefore now be marketed as a generic drug.
Continue reading
Tag: “Fingolimod”
ECTRIMS 2022 (3) – Autologous Hematopoietic Stem Cell Transplantation versus Highly Effective MS Therapies
Autologous hematopoietic stem cell transplantation (AHSCT) is a topic of intense interest among patients. To explain briefly again: Autologous hematopoietic stem cell transplantation (AHSCT) is not about replacement or repair of nerve tissue. This possibility
Continue reading
Booster Vaccination (3rd Vaccination against SARS-CoV2)
I would have very much wished not to have to write about this complex of topics anymore – but the current situation makes the topic of vaccination against COVID19 very topical again – and the
Continue reading
ECTRIMS 2021 (2): Vaccination in Multiple Sclerosis – Joint Consensus from ECTRIMS and EAN
The pandemic and the discussions about vaccinating MS patients against COVID19 have shown the need for a common European approach regarding recommendations for vaccinating MS sufferers. Therefore, after the last ECTRIMS Congress in 2020, representatives
Continue reading
ECTRIMS 2021 (4): When to stop therapy, when to extend the interval?
How long should immunotherapy for MS be continued? When can therapy be stopped? These are questions that not only concern MS patients but also many neurologists. Of course, one can take the position that long-lasting
Continue reading ECTRIMS 2021 (1): Vaccination against SARS-CoV2
This year, the ECTRIMS Congress was again held virtually due to the pandemic. While this was a pity, as large international congresses thrive on the personal exchange between doctors and scientists, there was still plenty
Continue reading
News about Siponimod (Mayzent)
Siponimod (Mayzent®) is a newly approved medication for the treatment of active secondary progressive multiple sclerosis. Like Fingolimod (Gilenya®), which is produced by the same manufacturer, Siponimod belongs to the class of so-called S1P receptor
Continue reading
The New S1P Modulators
In addition to the study data from Ofatumumab, which I had already reported on (see DocBlog post from September 2019), another new study program was presented at ECTRIMS 2019 in Stockholm. It is the so-called
Continue reading Approval of Siponimod in the USA and Europe – the vote of the regulatory authorities
The new MS drug Siponimod, the further development of Fingolimod (Gilenya®), was recently approved by the Food and Drug Administration (FDA) in the USA and has been available there for some time for MS patients
Continue readingGilenya – Lymphocyte Levels in Clinical Practice
Lymphocyte levels also play an important role in monitoring the active substance Fingolimod (Gilenya). However, the considerations here are quite different from those for Dimethyl fumarate (Tecfidera – Lymphocyte levels in clinical practice from March
Continue reading
